

# Q2 2021 Highlights July 27, 2021

# Safe Harbor for Forward-Looking Statements and Use of Document:

# Scientific

#### Safe Harbor for forward-looking statements:

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP, operational and organic revenue growth rates; GAAP and adjusted EPS for the third quarter and full year 2021; our financial performance; our business plans and product performance; and the impact of the COVID-19 pandemic on the company's results of operations. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business extrage and may cause actual results to differ materially from these contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences can be found in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed or to be filed with the Securities and Exchange Commission under the headings "Risk Factors" and "Safe Harbor for Forward-Looking Statements." Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

#### **Non-GAAP Measures:**

This document contains non-GAAP measures (denoted with \*) in talking about our Company's performance. The reconciliations of those non-GAAP measures to their most comparable GAAP measures are contained within this document including appendices attached to the end of this presentation or in our earnings release.

Operational net sales growth excludes the impact of foreign currency fluctuations. Organic net sales growth excludes the impact of foreign currency fluctuations as well as net sales from the acquisition of Preventice Solutions, Inc. (Preventice) in Q1 2021, as well as prior period net sales from the intrauterine health franchise and Specialty Pharmaceuticals business, divested in Q2 2020 and Q1 2021, respectively. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior period amounts to conform to the current year's presentation which had an immaterial impact on previously reported Emerging Markets net sales.

#### **Medical Devices:**

We have three historical reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices).

#### **Specialty Pharmaceuticals**

On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business. Our consolidated net sales include Specialty Pharmaceuticals up to the date of the closing of the transaction. Specialty Pharmaceuticals net sales were substantially U.S. based and presented as a stand-alone operating segment alongside our Medical Device reportable segments.

#### Use of Document:

This document contains certain highlights with respect to our second quarter 2021 performance and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended June 30, 2021 located in the investor section of our website at <u>www.bostonscientific.com</u> and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 to be filed with the Securities and Exchange Commission.

Amounts reported in millions within this presentation are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

# Q2 2021 Highlights

# Scientific

### Financial Highlights

- Net sales growth Y/Y vs. 2020:
  - +53.6% as reported, +49.6% operational\*, +52.4% organic\*
- Earnings per share:
  - GAAP: \$0.12 vs. \$(0.11) Q2:20
  - Adjusted\*: \$0.40 vs. \$0.08 Q2:20

#### • Gross margin:

- GAAP: 69.3%, 880 bps Y/Y
- Adjusted\*: 70.5%, 740 bps Y/Y

#### • Operating margin:

- GAAP: 8.5%, +1,210 bps Y/Y
- Adjusted\*: 25.1%, +1,250 bps Y/Y
- Q3 2021 guidance vs. Q3 2020:
  - GAAP net sales growth: 12% 14%
  - GAAP EPS: \$0.20 \$0.22
  - Organic\* net sales growth: 12% 14%
  - Adjusted EPS\*: \$0.39 \$0.41


#### • FY 2021 guidance vs. FY 2020:

- GAAP net sales growth: 21% 22%
- GAAP EPS: \$0.79 \$0.83
- Organic\* net sales growth: 19% 20%
- Adjusted EPS\*: \$1.58 \$1.62

### **Operational Highlights**

- Completed EU CE Mark for the EXALT<sup>™</sup> Model B Single-Use Bronchoscope and initiated EU launch of SpaceOAR Vue<sup>™</sup> Hydrogel.
- At TVT, announced positive 2-year results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the WATCHMAN FLX™ LAAC Device for patients with non-valvular atrial fibrillation (NVAF), and presented late-breaking clinical trial results for the Early Neo2 Registry of the ACURATE neo2™ Aortic Valve System which demonstrated excellent procedural outcomes, including a low permanent pacemaker implementation and low rate of paravalvular leakage.
- Completed patient enrollment in the OPTION clinical trial, a randomized controlled study comparing WATCHMAN FLX<sup>™</sup> to first-line oral anticoagulants for 1,600 NVAF patients.
- Began enrollment in the AGENT IDE trial, the first randomized study in the U.S. designed to assess safety and effectiveness of the AGENT<sup>™</sup> DCB vs. plain old balloon angioplasty in patients with in-stent restenosis.
- Commenced enrollment in the ELEGANCE registry, a post-market study gathering real-world clinical evidence to assess long-term outcomes of patients following treatment with either Ranger™ DCB or Eluvia™ DES.
- Announced **one-year follow-up results of the COMBO** randomized controlled clinical trial at NANS, demonstrating that Combination Therapy delivered by the Spectra WaveWriter<sup>™</sup> SCS System achieved a **sustained**, **high level of clinical and functional success**.
- Exercised option to acquire the remaining shares of Farapulse, Inc which is expected to close Q3:21E and will complement the existing Boston Scientific Electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation System.
- Announced the election of **David S. Wichmann**, former chief executive officer of UnitedHealth Group, to the company's board of directors.

# WW Net Sales by Segment and Business



Scientific

### WW Net Sales Detail



#### Three Months Ended June 30, 2021 and 2020

Q2 2021	Q2 2020	As Reported Basis	Less: Impact of Foreign Currency Fluctuations	Operational Basis	Less: Impact of Recent Acquisitions / Divestitures	Organic Basi
\$ 551	\$ 348	58.5 %	44%	54 1 %	— %	54.1
•	•					70.8
948	576	64.6 %	4.0 %	60.6 %	(0.1)%	60.7
524	351	49.2 %	4.3 %	44.9 %	13.8 %	31.2
95	51	85.8 %	7.1 %	78.7 %	— %	78.7
247	122	101.5 %	3.6 %	98.0 %	— %	98.0
866	525	65.0 %	4.4 %	60.6 %	9.2 %	51.4
790	495	59.8 %	4.6 %	55.2 %	— %	55.2
473	340	39.1 %	3.5 %	35.6 %	— %	35.6
1,263	834	51.4 %	4.2 %	47.2 %	%	47.2
3,077	1,935	59.0 %	4.2 %	54.9 %	2.5 %	52.4
	68	(100.0)	— %	(100.0)	(100.0)%	_
\$ 3,077	\$ 2,003	53.6 %	4.0 %	49.6 %	(2.8)%	52.4
\$ 359	\$ 268	33.8 %	8.0 %	25.8 %		
	2021 \$ 551 397 948 524 95 247 866 790 473 1,263 3,077 	2021 2020   \$ 551 \$ 348   397 228   948 576   524 351   95 51   247 122   866 525   790 495   473 340   1,263 834   3,077 1,935   — 68	20212020Basis $\$$ 551 \$34858.5 %39722873.9 %94857664.6 %52435149.2 %955185.8 %247122101.5 %86652565.0 %79049559.8 %47334039.1 %1,26383451.4 %3,0771,93559.0 %-68(100.0)	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

# MedSurg Performance Summary

Measure (\$ in millions)	Q2 2021	Q2 2020	Change Y/Y
Reported Net Sales	\$948M	\$576M	+64.6%
Operating Margin \$	\$363M	\$173M	+109.6%
Operating Margin %	38.3%	30.1%	+820 bps

Boston

#### Q2 2021 Highlights

- Endoscopy: Global net sales +58.5% as reported, +54.1% Y/Y operational\* and organic\*
- Grew double digits vs. 2019 across all major franchises with notable strength in Biliary, Hemostasis, and Infection Prevention due to differentiated product portfolio headlined by AXIOS<sup>™</sup>, SpyGlass<sup>™</sup> DS, and Resolution<sup>™</sup> hemostasis clip.
- Completed CE Mark for EXALT<sup>™</sup> Model B which has garnered positive early launch feedback and remain on track to launch in the U.S. in H2:21E.
- Urology and Pelvic Health: Global net sales +73.9% as reported, +70.4% Y/Y operational\*, +70.8% organic\*
  - Strong Q2 growth vs. 2019 balanced across the Stone, Prostate Health, and Pelvic Health franchises; enthusiastic that the Lumenis acquisition will expand category-leading Urology portfolio with its differentiated laser technology.
  - Within Prostate Health, momentum continued for Rezūm and within the SpaceOAR business, where growth was supported by the ongoing launch of next generation SpaceOAR Vue™ hydrogel in the U.S. and recent launch in EU.

# Rhythm and Neuro Performance Summary



Measure (\$ in millions)	Q2 2021	Q2 2020	Change Y/Y
Reported Net Sales	\$866M	\$525M	+65.0%
Operating Margin \$	\$168M	\$32M	+426.8%
Operating Margin %	19.3%	6.1%	+1,320 bps

#### Q2 2021 Highlights

- Cardiac Rhythm Management: Global net sales +49.2% as reported, +44.9% Y/Y operational\*, +31.2% organic\*
  - Estimate CRM performance was slightly below the overall market, and inclusive of a temporary impact from the recent EMBLEM<sup>™</sup> S-ICD physician advisories; launched enhanced S-ICD electrode and anticipate improved performance in overall CRM in H2:21E.
  - LUX-Dx<sup>™</sup> ICM continues to perform well and gain market share; additionally, pleased with the strong growth and execution of the Preventice team and continue to anticipate FY:21E growth in that business of at least 20% vs. 2020.

#### • Electrophysiology: Global net sales +85.8% as reported, +78.7% Y/Y operational\* and organic\*

- Sales grew double digits vs. 2019 as we estimate international sales outpaced the market; international sales strength was driven by the ongoing launches of POLARx<sup>™</sup>, a second generation single-shot cryoablation catheter, and STABLEPOINT<sup>™</sup>, a novel force-sensing therapeutic catheter with DirectSense.
- Exercised the option to acquire Farapulse, Inc., a leading company in pulsed field ablation and the only commercially approved pulsed ablation product in the EU.
- Neuromodulation: Global net sales +101.5% as reported, +98.0% Y/Y operational\* and organic\*
  - Bullish on the next gen WaveWriter Alpha<sup>™</sup> (SCS) launch and Vercise Genus<sup>™</sup> platform which expands MRI capabilities in the rechargeable and non-rechargeable segments.
  - Beyond advancing outcomes for our existing indications, commenced enrollment in SOLIS study in Q1, focused on non-surgical back population, and look forward to beginning our painful diabetic peripheral neuropathy (DPN) clinical study by the end of this year.

# **Cardiovascular Performance Summary**



Measure (\$ in millions)	Q2 2021	Q2 2020	Change Y/Y
Reported Net Sales	\$1,263M	\$834M	+51.4%
Operating Margin \$	\$418M	\$186M	+125.0%
Operating Margin %	33.1%	22.3%	+1,080 bps

#### Q2 2021 Highlights

- Interventional Cardiology: Global net sales +59.8% as reported, +55.2% Y/Y operational\* and organic\*
- The WATCHMAN<sup>™</sup> franchise accelerated sequentially primarily due to increasing hospital and physician utilization rates in the U.S. as nearly all U.S. accounts have fully transitioned from WATCHMAN 2.5<sup>™</sup> and are now using FLX exclusively; pleased with the two-year results of PINNACLE FLX and remain excited about the outlook for the WATCHMAN<sup>™</sup> franchise.
- In TAVR, ACURATE neo2<sup>™</sup> launch continues to do well in EU supported by positive real-world data presented at Euro PCR and reiterated in the Early Neo2 Registry at TVT; SENTINEL<sup>™</sup> achieved its highest quarterly sales to date.
- Strength in Complex PCI with key products such as ROTAPRO<sup>™</sup> and IVUS<sup>™</sup> were offset by DES performance, impacted by China tenders and global price pressures.
- Peripheral Interventions: Global net sales +39.1% as reported, +35.6% Y/Y operational\* and organic\*
  - Strong growth in the quarter was fueled by breadth of category-leading portfolio and robust cadence of ongoing product launches headlined by TheraSphere™ growth of >30% vs. 2019, double digit Varithena™ growth and varicose vein share gain, and record sales in the drug-eluting portfolio.

•

## BSX: Q2:21 Net Sales vs. 2020 and 2019

	Q2:21 Sales	Organic <sup>*</sup>	<sup>•</sup> Growth
		vs Q2:20	vs Q2:19
Endoscopy	\$551M	54%	15%
UroPH	\$397M	71%	16%
CRM	\$524M	31%	(6)%
EP	\$95M	79%	10%
NM	\$247M	98%	14%
IC	\$790M	55%	10%
PI	\$473M	36%	10%
Total Company	\$3,077M	52%	9%

Organic net sales growth excludes the impact of acquisitions and divestitures for which there are no comparable period net sales.

2021 organic growth vs. 2020 excludes:

- Preventice, acquired March 1, 2021
- Intrauterine health franchise, divested Q2 2020
- Specialty Pharmaceuticals, divested March 1, 2021

2021 organic growth vs. 2019 excludes:

- Preventice, acquired March 1, 2021
- Vertiflex, acquired May 2019
- BTG Interventional Medicine, acquired mid-August 2019
- Specialty Pharmaceuticals, acquired mid-August 2019, divested Mar 1, 2021
- Global embolic microspheres portfolio, divested in mid-August 2019
- Intrauterine health franchise, divested Q2 2020


Boston

## Living Our Values: ESG Update

# Scientifi

### Playing Our Part: Combating Racism

### \$3.5 Million Multiyear Strategy



Q2 Awards



COMBATING RACISM STRATEGY

Community Expand the conversation on anti-racism and support social justice organizations

### **Economic Empowerment**

Accelerate the development of lack-owned businesse



Education Educate and create professional opportunities for Black youth



Health Care Disparities Address health care disparities in the community

Government/Policies Advocate for change

#### **Global Signature Health Grants**

"We are incredibly thankful for Boston Scientific's commitment to improving the world's health and for a partnership that is helping people around the world access the care they need."

Rabih Torbay, president and CEO, Project HOPE



To date, our efforts have helped train. +3,500 community health workers and provided screenings for +23,000 people.

**Glassdoor Top CEOs 2021 Employees' Choice** 

Seramount Best **Companies for Multicultural Women** 

**DEI Best Place to Work for Disability Inclusion 2021** 

Boston Scientific Confidential -- For Internal Use Only. Do Not Copy, Display or Distribute Externally 10

### Income Statement Information Non-GAAP Reconciliation

#### Three Months Ended June 30, 2021 (unaudited)

		Amortization	Intangible Asset Impairment	Acquisition / Divestitures- Related Net Charges	Restructuring and Restructuring- Related Net Charges	Litigation- Related Net Charges	Investment Portfolio Net Losses	EU MDR Implementation	Deferred Tax Expenses	Discrete	Adjusted*'
in millions, except per share data	GAAP Results	Expense	Charges	(Credits)	(Credits)	(Credits)	(Gains)	Costs	(Benefits)	Tax Items	Results
Net sales	\$ 3,077			_							\$ 3,077
Cost of products sold	945			7	22			8			908
Gross profit	2,132	—	—	(7)	(22)	—	-	(8)	-	_	2,169
Gross margin	69.3 %										70.5 %
Selling, general and administrative expenses	1,121			11	13						1,096
SG&A as a percentage of sales	36.4 %										35.6 %
Research and development expenses	298			6				4			288
R&D as a percentage of sales	9.7 %										9.4 %
Royalty expense	12										12
Royalty expense as a percentage of sales	0.4 %										0.4 %
Amortization expense	180	180									—
Intangible asset impairment charges	45		45								—
Contingent consideration expense (benefit)	(85)			(85)							—
Restructuring charges (credits)	3				3						—
Gain/loss on divestitures	(2)		_	(2)							—
Litigation-related charges (credits)	298					298					—
	1,870	180	45	(70)	16	298	_	4	—	_	1,396
Operating income (loss)	262	(180)	(45)	63	(39)	(298)	_	(12)	_	_	773
Operating margin	8.5 %										25.1 %
Other income (expense):											
Interest expense	(86)										(86)
Other, net	(26)	_		1			(6)			_	(21)
Income (loss) before taxes	149	(180)	(45)	64	(39)	(298)		(12)	_	_	665
Income tax expense (benefit)	(37)	(19)	(6)	(1)	(4)	(69)	(1)	(1)	25	(35)	74
Net income (loss)	186	(161)	(39)	65	(35)	(229)	(5)	(11)	(25)	35	591
Preferred stock dividends	(14)										(14)
Net income (loss) available to common stockholders	\$ 172	\$ (161)	\$ (39)	\$ 65	\$ (35)	\$ (229)	\$ (5)	\$ (11)	\$ (25)	\$ 35	\$ 577
Net income (loss) per diluted common share	\$ 0.12	\$ (0.11)		\$ 0.05	\$ (0.02)		\$ (0.00)	\$ (0.01)	\$ (0.02)	\$ 0.02	\$ 0.40
Weighted average diluted shares outstanding	1,432.5	1,432.5	1,432.5	1,432.5	1,432.5	1,432.5	1,432.5	1,432.5	1,432.5	1,432.5	1,432.5

Boston

For the three months ended June 30, 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited condensed consolidated statements of operations, for purposes of calculating net income available to common stockholders.

## **Income Statement Information**

#### **Non-GAAP Reconciliation**

#### Six Months Ended June 30, 2021 (unaudited)

		Amortization	Intangible Asset Impairment	Acquisition / Divestitures- Related Net Charges	Restructuring and Restructuring -Related Net Charges	Litigation- Related Net Charges	Investmen t Portfolio Net Losses	EU MDR Implementation	Deferred Tax Expenses	Discrete	Adju	usted*'
in millions, except per share data	GAAP Results	Expense	Charges	(Credits)	(Credits)	(Credits)	(Gains)	Costs	(Benefits)	Tax Items	Re	sults
Net sales	\$ 5,829										\$	5,829
Cost of products sold	1,839			21	40			15				1,763
Gross profit	3,990	—	—	(21)	(40)	—	_	(15)	-	-		4,066
Gross margin	68.4 %											69.8 %
Selling, general and administrative expenses	2,139			51	40			_				2,048
SG&A as a percentage of sales	36.7 %											35.1 %
Research and development expenses	574			15	—			8				552
R&D as a percentage of sales	9.9 %											9.5 %
Royalty expense	24											24
Royalty expense as a percentage of sales	0.4 %											0.4 %
Amortization expense	365	365										—
Intangible asset impairment charges	45		45									—
Contingent consideration expense (benefit)	(91)			(91)								—
Restructuring charges (credits)	8				8							—
Gain/loss on divestitures	(9)			(9)								—
Litigation-related charges (credits)	302					302						—
	3,358	365	45	(34)	48	302	_	8	_	_		2,625
Operating income (loss)	632	(365)	(45)	13	(88)	(302)	_	(23)	-	_		1,442
Operating margin	10.8 %											24.7 %
Other income (expense):												
Interest expense	(168)			—								(168)
Other, net	11	—		199			(152)	_				(37)
Income (loss) before taxes	474	(365)	(45)	212	(88)	(302)	(152)	(23)	_	_		1,237
Income tax expense (benefit)	(53)	\$ (37)	\$ (6)	\$ (7)	\$ (10)	\$ (69)	\$ (35)	(2)	43	(38)		108
Net income (loss)	\$ 527	\$ (328)			\$ (79)	\$ (233)	\$ (117)	\$ (20)	\$ (43)	\$ 38	\$	1,129
Preferred stock dividends	\$ (28)										\$	(28)
Net income (loss) available to common stockholders	\$ 500	\$ (328)	\$ (39)	\$ 219	\$ (79)	\$ (233)	\$ (117)	\$ (20)	\$ (43)	\$ 38	\$	1,102
Net income (loss) per diluted common share	\$ 0.35	\$ (0.23)	\$ (0.03)	\$ 0.15	\$ (0.05)	\$ (0.16)	\$ (0.08)	\$ (0.01)	\$ (0.03)	\$ 0.03	\$	0.77
Weighted average diluted shares outstanding	1,431.7	1,431.7	1,431.7	1,431.7	1,431.7	1,431.7	1,431.7	1,431.7	1,431.7	1,431.7	1	1,431.7

For the six months ended June 30, 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited condensed consolidated statements of operations, for purposes of calculating net income available to common stockholders.

12 Q2 2021 Financial & Operational Highlights | July 27, 2021

Margin rates are based on actual, non-rounded amounts and may not recalculate precisely.



## **Balance Sheet & Cash Flow Metrics**



Day	s Sales	Outstar	nding (D	SO)	Adjusted Fre	e Cash Flow*
Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Q2 2021	Q2 2020
50	53	52	55	66	\$838M	\$340M
						I
		ory on H			Capital Ex	
Days	s Invent	ory on H	land (D	IOH)	Capital Ex	penditures
Days	s Invent	ory on H Dec	land (D	IOH)	Capital Ex	penditures

To supplement Boston Scientific's consolidated financial statements presented on a GAAP basis, the Company discloses certain non-GAAP financial measures. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.

Boston

A reconciliation of the non-GAAP financial measures included in this document to the corresponding GAAP measures follows in the Appendix. In addition, an explanation of the ways in which Boston Scientific management uses these supplemental non-GAAP measures to evaluate its business and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included under "Use of Non-GAAP Financial Measures" in the company's most recent earnings release filed with the SEC on Form 8-K. This non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.



# Appendix A Sales Detail

### Three Months Ended June 30, 2021 and 2020



				Year-over-Year Change	
n millions)	Q2 2021	Q2 2020	Reported Basis	Less: Impact of Foreign Currency Fluctuations	Operational Basis
MEDSURG SEGMENT:					
ENDOSCOPY					
UNITED STATES \$	316	\$ 190	66.7 %	— %	66.7
INTERNATIONAL	235	158	48.6 %	9.6 %	39.1
WORLDWIDE <u>\$</u>	551	\$ 348			
UROLOGY AND PELVIC HEALTH					
UNITED STATES \$	285	\$ 162	75.3 %	— %	75.3
INTERNATIONAL	112	66	70.4 %	12.0 %	58.4
WORLDWIDE \$	397	\$ 228			
RHYTHM AND NEURO SEGMENT:					
CARDIAC RHYTHM MANAGEMENT					
UNITED STATES \$	314	\$ 208	50.9 %	— %	50.9
INTERNATIONAL	210	143	46.8 %	10.5 %	36.3
WORLDWIDE \$	524	\$ 351			
ELECTROPHYSIOLOGY					
UNITED STATES \$	34	\$ 22	57.0 %	— %	57.0
INTERNATIONAL	62	30	106.6 %	12.1 %	94.4
WORLDWIDE \$	95	\$ 51			
UNITED STATES \$	194	\$ 100	94.4 %	— %	94.4
INTERNATIONAL	53	\$ 100 23	133.0 %	% 19.3 %	113.8
WORLDWIDE \$		\$ 122	155.0 %	19.5 //	115.0
———————————————————————————————————————		<u> </u>			
		<b>A</b> 100	110.0.0/	0/	110.0
UNITED STATES \$ INTERNATIONAL	398 392	\$ 189 306	110.6 % 28.4 %	— % 7.4 %	110.6 20.9
WORLDWIDE \$	<u> </u>		20.4 %	1.4 %	20.9
	790	\$ 495			
PERIPHERAL INTERVENTIONS					
UNITED STATES \$	260	\$ 189	37.8 %	— %	37.8
INTERNATIONAL	213	151	40.8 %	8.0 %	32.8
WORLDWIDE	473	\$ 340			
SPECIALTY PHARMACEUTICALS:					
UNITED STATES \$	—	\$ 60	(100.0)%	— %	(100.0
INTERNATIONAL		8	— %	— %	_
WORLDWIDE \$	—	\$ 68			

### Six Months Ended June 30, 2021 and 2020



				Year-over-Year Change	
				Less: Impact of Foreign Currency	
n millions) MEDSURG SEGMENT:	2021	2020	As Reported Basis	Fluctuations	Operational Basis
ENDOSCOPY					
UNITED STATES \$	596	\$ 445	33.9 %	— %	33.9
INTERNATIONAL	454	345	31.7 %	8.2 %	23.5
WORLDWIDE \$	1,050	\$ 790	• · · · · ·		
UROLOGY AND PELVIC HEALTH					
UNITED STATES \$	542	\$ 400	35.6 %	— %	35.6
INTERNATIONAL	216	161	34.4 %	8.8 %	25.6
WORLDWIDE \$	758	\$ 560			
RHYTHM AND NEURO SEGMENT:			-		
CARDIAC RHYTHM MANAGEMENT					
UNITED STATES \$	590	\$ 463	27.4 %	— %	27.4
INTERNATIONAL	403	325	23.9 %	8.6 %	15.4
WORLDWIDE	993	\$ 788			
ELECTROPHYSIOLOGY					
UNITED STATES \$	64	\$ 53	19.6 %	— %	19.6
INTERNATIONAL	115	72	58.6 %	9.3 %	49.3
WORLDWIDE	179	\$ 126			
NEUROMODULATION					
UNITED STATES \$	345	\$ 250	37.8 %	— %	37.8
INTERNATIONAL	99	63	58.1 %	12.5 %	45.5
WORLDWIDE	444	\$ 313			
CARDIOVASCULAR SEGMENT:					
INTERVENTIONAL CARDIOLOGY					
UNITED STATES \$	741	\$ 486	52.4 %	— %	52.4
INTERNATIONAL	745	642	16.1 %	6.2 %	9.8
WORLDWIDE	1,486	\$ 1,128			
PERIPHERAL INTERVENTIONS					
UNITED STATES \$	498	\$ 413	20.7 %	— %	20.7
INTERNATIONAL	407	319	27.6 %	7.0 %	20.6
WORLDWIDE \$	906	\$ 732			
SPECIALTY PHARMACEUTICALS:					
UNITED STATES \$	10	\$ 97	(90.2)%	— %	(90.2
INTERNATIONAL	4	\$ 12	(68.1)%	— %	(68.1



# Appendix B Income Statement Information

## Appendix B - Income Statement Information Margins



		Three Months Ended					
Adjusted Gross Margin	6/30/2021	6/30/2020	Basis Points Change				
Gross Margin, as reported	69.3 %	60.5 %	880				
Less: Non-GAAP adjustments	(1.2)%	(2.6)%					
Adjusted Gross Margin	70.5 %	63.1 %	740				

		Three Months Ended					
Adjusted Operating Margin	6/30/2021	6/30/2020	Basis Points Change				
Operating Margin, as reported	8.5 %	(3.6)%	1,210				
Less: Non-GAAP adjustments	(16.6)%	(16.2)%					
Adjusted Operating Margin	25.1 %	12.6 %	1,250				

		Three Months Ended			
Adjusted SG&A as a percentage of Sales	6/30/2021	6/30/2020	Basis Points Change		
SG&A as a percentage of Sales, as reported	36.4 %	39.9 %	(350)		
Less: Non-GAAP adjustments	0.8 %	1.4 %			
Adjusted SG&A as a percentage of Sales	35.6 %	38.5 %	(290)		

	Three Months Ended
Adjusted Tax Rate	6/30/2021
Tax Rate, as reported	(24.9)%
Less: Non-GAAP adjustments	(36.0)%
Adjusted Tax Rate	11.1 %

## Appendix B - Income Statement Information Segment Operating Income

<u>Note:</u> We measure and evaluate our reportable segments based on net sales of reportable segments, operating income of reportable segments, excluding intersegment profits, and operating income of reportable segments as a percentage of net sales of reportable segments. Operating income of reportable segments is defined as operating income of reportable segments divided by net sales of reportable segments. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported *Income (loss) before income taxes* in our accompanying unaudited consolidated statements of operations and are included in the reconciliation below.

Boston

SEGMENT NET SALES (dollars in millions)	Q2 2021	Q2 2020
MedSurg	\$ 948	\$ 576
Rhythm & Neuro	866	525
Cardiovascular	 1,263	 834
Total net sales of reportable segments (Medical Devices)	3,077	1,935
All other (Specialty Pharmaceuticals)	_	68
Consolidated net sales	\$ 3,077	\$ 2,003

SEGMENT OPERATING INCOME (dollars in millions)	Q2 2021	% of Segment Sales	Q2 2020	% of Segment Sales	YoY Change (%)	YoY Change (bps)	Less: Fx Impact	YoY Change, excl. Fx
MedSurg	\$ 363	38.3 % \$	173	30.1 %	8.2 %	822	0.3%	7.9%
Rhythm & Neuro	168	19.3 %	32	6.1 %	13.3 %	1329	0.9%	12.4%
Cardiovascular	418	33.1 %	186	22.3 %	10.8 %	1084	0.3%	10.5%
Total operating income of reportable segments (Medical Devices)	949		391					
All other (Specialty Pharmaceuticals)	_		49					
Unallocated amounts:								
Corporate expenses, including hedging activities	(176	)	(189)					
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs	(331	)	(125)					
Amortization expense	, (180	,	(197)					
Operating income (loss)	\$ 262	<u> </u>	(71)					)



# Appendix C Additional Non-GAAP Reconciliations

## Appendix C - Additional Reconciliations Adjusted Free Cash Flow



in millions	Three Months Ended			
Adjusted Free Cash Flow	6/30/2021 6/30/202			
Operating cash flow, reported	\$	643 \$	269	
Less: Purchases of property, plant and equipment		105	68	
Add: Proceeds on disposals of property, plant and equipment		3	1	
Free Cash Flow		541	203	
Plus: Restructuring and restructuring-related payments		40	26	
Plus: Acquisition-related payments		36	59	
Plus: EU medical device regulation payments		12	7	
Plus: Special tax payments (refunds/credits)		42	4	
Plus: Litigation-related settlements		167	42	
Adjusted Free Cash Flow	\$	838 \$	340	

# Appendix C - Additional Reconciliations



Estimated Tax Rate	FY 2021
Tax Rate, as reported	7 %
Less: Non-GAAP adjustments	(3)%
Adjusted Tax Rate	10 %

	Three Months Ended	
China Net Sales Growth Q2'21 vs. Q2'19	June 30	
Net sales growth, as reported	23 %	
Less: Impact of foreign currency fluctuations	7 %	
Net sales growth, operational	16 %	

	Three Months Ended
International EP Net Sales Growth Q2'21 vs. Q2'19	June 30
Net sales growth, as reported	35 %
Less: Impact of foreign currency fluctuations	6 %
Net sales growth, operational	29 %

	Three Months Ended
U.S. Organic Net Sales Growth Q2'21 vs. Q2'19	June 30
Net sales growth, as reported	22 %
Less: Impact of recent acquisitions/divestitures	10 %
Net sales growth, organic	12 %

# Appendix C - Additional Reconciliations



	Q3 2021 Estima vs. Q3 2019			1 Estimate ear 2019
Q3 and Full Year 2021 Estimated Net Sales Growth vs. 2019	(Low)	(High)	(Low)	(High)
Reported sales growth	10 %	12 %	12 %	13 %
Less: Impact of foreign currency fluctuations & certain acquisitions/divestitures	5 %	5 %	6 %	6 %
Organic sales growth	5 %	7 %	6 %	7 %

Q2 2021 vs. Q2 2019 Net Sales	Q	2 2021	Q2 2019	Reported Growth	Less: Impact of foreign currency fluctuations & recent acquisitions/ divestitures	Organic Growth
Endoscopy	\$	551	470	17 %	2 %	15 %
Urology and Pelvic Health		397	348	14 %	(2)%	16 %
Cardiac Rhythm Management		524	498	5 %	12 %	(6)%
Electrophysiology		95	84	13 %	3 %	10 %
Neuromodulation		247	204	21 %	7 %	14 %
Interventional Cardiology		790	706	12 %	2 %	10 %
Peripheral Interventions		473	320	48 %	38 %	10 %
Specialty Pharmaceuticals		—	n/a	n/a	n/a	n/a
Total Company	\$	3,077 \$	2,631	17 %	8 %	9 %

Q2 2021 vs. Q2 2019 Net Sales	Q2 2021	Q2 2019	Reported Growth	Less: Impact of foreign currency fluctuations	Operational Growth
United States	\$ 1,800	1,478	22 %	— %	22 %
EMEA (Europe, Middle East and Africa)	662	571	16 %	7 %	9 %
Asia-Pacific (APAC)	520	481	8 %	4 %	4 %
Emerging Markets	359	318	13 %	2 %	11 %

### **BSX: Acronym Reference Guide**



BPH	Benign Prostatic Hyperplasia
CLI	Critical Limb Ischemia
CRT-D	Cardiac Resynchronization Therapy Defibrillator
DBS	Deep Brain Stimulation
DCB	Drug-Coated Balloon
DES	Drug-Eluting Stent
DVT	Deep Vein Thrombosis
ERCP	Endoscopic Retrograde Cholangiopancreatography
ICD	Implantable Cardioverter-defibrillator
ICM	Insertable Cardiac Monitor
IDE	Investigation Device Exemption
LAAC	Left Atrial Appendage Closure
PCI	Percutaneous Coronary Interventions
PE	Pulmonary Embolism
SCS	Spinal Cord Stimulation
SUI	Stress Urinary Incontinence
TAVR	Transcatheter Aortic Valve Replacement